Oric director-linked entity sells 300 ORIC shares
Oric Pharmaceuticals director Richard A. Heyman, through an associated entity, reported a small insider sale of Oric Pharmaceuticals, Inc. common stock.
Rhea-AI Filing Summary
Oric Pharmaceuticals director Richard A. Heyman, through an associated entity, reported a small insider sale of Oric Pharmaceuticals, Inc. common stock.
RAHD Capital, LLC, an entity for which Heyman has voting and investment power, sold 300 shares of common stock at $12.00 per share in an open-market transaction on July 6, 2026, executed under a pre-arranged Rule 10b5-1 trading plan. After this sale, RAHD Capital, LLC held 212,772 shares indirectly, while Heyman also reported a separate direct holding entry showing 41,800 shares owned directly.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 300 shares
Net Sell
2 txns
Insider
Heyman Richard A.
Role
Director
Sold
300 shs ($4K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 300 | $12.00 | $4K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 212,772 shares (Indirect, See footnote);
Common Stock — 41,800 shares (Direct)
Footnotes (2)
- F1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.
- F2. The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.
Key Figures
Shares sold: 300 shares
Sale price: $12.00 per share
Indirect holdings after sale: 212,772 shares
+1 more
4 metrics
Shares sold
300 shares
Open-market sale on July 6, 2026
Sale price
$12.00 per share
Common stock transaction code S
Indirect holdings after sale
212,772 shares
Held by RAHD Capital, LLC following transaction
Direct holdings
41,800 shares
Common stock directly owned after holding entry
Key Terms
Rule 10b5-1 trading plan, open-market sale, indirect ownership, Common Stock
4 terms
Rule 10b5-1 trading plan regulatory
"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action: open-market sale for 300.0000 shares of Common Stock at 12.0000 per share."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
indirect ownership financial
"direct_or_indirect: I, nature_of_ownership: See footnote, indicating indirect ownership through RAHD Capital, LLC."
Common Stock financial
"security_title: Common Stock for both the holding entry and the sale transaction."
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did ORIC director Richard A. Heyman report?
Richard A. Heyman reported an indirect open-market sale of 300 Oric Pharmaceuticals common shares at $12.00 each. The sale was executed by RAHD Capital, LLC, an entity he controls, under a pre-arranged Rule 10b5-1 trading plan dated July 6, 2026.
Was the ORIC insider sale made under a Rule 10b5-1 trading plan?
Yes, the 300-share sale of Oric Pharmaceuticals stock was executed under a Rule 10b5-1 trading plan. The plan was adopted by Richard A. Heyman and RAHD Capital, LLC, indicating the transaction was pre-arranged rather than an opportunistic, discretionary market trade.
What is the reported sale price for the ORIC insider transaction?
The reported sale price for the Oric Pharmaceuticals insider transaction was $12.00 per share. RAHD Capital, LLC sold 300 common shares at this price in an open-market or private transaction, as described in the Form 4 transaction details and code explanation.
AI-generated analysis. How Rhea-AI works. Not financial advice.
